All Articles

On April 4, 2019, the FDA approved a new indication for palbociclib (Ibrance; Pfizer), an oral kinase inhibitor, for men with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer. Read More ›

A chimeric antigen receptor (CAR) T-cell therapy that targets CD19 and CD22 molecules has demonstrated safety and efficacy, in patients with relapsed or refractory B-cell precursor acute lymphoblastic lymphoma (ALL), with response rates consistent with CAR T-cell therapies that target CD19 alone. Read More ›

On March 11, 2019, the FDA approved trastuzumab-qyyp (Trazimera; Pfizer) as the fourth biosimilar to trastuzumab (Herceptin; Genentech) for the treatment of patients with HER2-positive breast cancer or HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. This approval was based on several studies confirming that trastuzumab-qyyp is biosimilar to the originator drug, Herceptin. Read More ›

A2-year duration of combination immunotherapy with ven­etoclax (Venclexta) and rituximab (Ri­tuxan) improved survival compared with standard-of-care chemoimmunotherapy combination with bendamustine (Ben­deka) plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), according to follow-up data from the MURANO clinical trial presented at ASH 2018. Early results were first presented at ASH 2017. Read More ›

Updated results from the safety lead-in of the phase 3 BEACON CRC clinical trial show a mature median overall survival (OS) of 15.3 months with the triple-drug regimen of encorafenib (Braftovi), a BRAF inhibitor; binimetinib (Mektovi), a MEK inhibitor; and cetuximab (Erbitux), an epidermal growth factor receptor (EGFR) inhibitor, for the treatment of patients with metastatic colo­rectal cancer (CRC) and BRAF V600E mutation. Read More ›

Selinexor has shown promising activity in very heavily pretreated patients with penta­refractory multiple myeloma. In the pivotal STORM Part 2 study, oral selinexor in combination with low-dose dexamethasone induced responses in 26.2% of patients. Read More ›

Adjuvant treatment with durvalumab (Imfinzi), a checkpoint inhibitor, in patients with residual disease after trimodal therapy for advanced esophageal or gastroesophageal junction (GEJ) adenocarcinoma was associated with a 79% 1-year relapse-free survival rate in a phase 2 clinical trial. Read More ›

Pharmacy standards will be applied to medical practices, regardless of whether they have a pharmacy licensed with their state Board of Pharmacy. Read More ›

In a first-in-human study of a novel bispecific T-cell engager (BiTE), AMG 420, when administered at a daily dose of 400 mcg, this novel drug-induced responses in 7 of 10 patients with heavily pretreated multiple myeloma in a phase 1 clinical trial, according to results presented at ASH 2018. Read More ›

The adjuvant use of the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1; Kadcyla) led to a clinically meaningful and statistically significant improvement in invasive disease-free survival (ie, survival free of invasive disease or death) compared with trastuzumab (Herceptin) in patients with HER2-­positive early-stage breast cancer and residual invasive disease, despite the use of neoadjuvant chemotherapy plus HER2-­targeted therapy, according to the preliminary results of the phase 3 KATHERINE trial. These findings were reported at the 2018 San Antonio Breast Cancer Symposium. Read More ›